The purpose of this study was to determine outcomes for 56 patients with inflammatory breast cancer (IBC) receiving high-dose chemotherapy (HDC) with cyclophosphamide, thiotepa and carboplatin (CTCb) with peripheral blood stem cell (PBSC) support. All patients received the same total amount of chemotherapy but there were differences in the sequence of therapy: 15 received induction chemotherapy, chemotherapy mobilization of PBSC and CTCb after surgery (adjuvant group) while 41 received induction chemotherapy with (n = 17) or without (n = 24) chemotherapy for mobilization of PBSC prior to surgery and CTCb after surgery (neoadjuvant group). Median time from diagnosis to HDC was 5.5 months (range 3.5-12.5). Fifty-one patients (91%) required admission to the hospital following HDC for a median of 11 days (range 5-25). There were two (4%) infectious deaths after HDC. Twenty-four patients (43%) have relapsed at a median of 18 months (range 8-50) from diagnosis resulting in death in 34%. The probabilities of overall (OS) and event-free survival (EFS) at 3 years for all 56 patients were 0.72 and 0.53, respectively, with a median followup of 44 months (range 15-76) from diagnosis. There were no differences in OS, EFS or patterns of relapse between patients in the adjuvant or neoadjuvant groups. These sequences of combined modality therapy incorporating HDC are comparable or superior to other intensive approaches for the treatment of IBC. Further improvements will be necessary to decrease systemic recurrences. Keywords: high-dose therapy; inflammatory breast cancer Multi-modality therapy is now the standard of care for patients with inflammatory breast cancer (IBC).
therapy has decreased local progression of disease but the majority of patients relapse at distant sites making eradication of microscopic metastatic disease the major challenge.
The potential value of high-dose chemotherapy (HDC) with hematopoietic stem cell support in patients with operable high-risk stage II-III non-inflammatory breast cancer has been reported. [19] [20] [21] [22] [23] [24] [25] [26] Evaluation of HDC with stem cell support in patients with IBC is a logical extension of these studies.
Results of autologous bone marrow (BM) transplantation for patients with IBC have been included in summaries of transplant results 27, 28 and reported by the International Bone Marrow Transplant Registry. 23, 29 Recently, there have been two single-center reports of outcomes for patients with stage IIIB IBC with HDC with BM or peripheral blood stem cell (PBSC) support. 30, 31 These studies, utilizing varying induction, mobilization and high-dose regimens have resulted in 3 year event-free survivals (EFS) ranging from 42 to 64%. 23, [27] [28] [29] [30] [31] In order to provide more baseline data the present report describes the results of HDC with PBSC support in 56 patients with stage IIIB IBC who have a median follow-up of 44 months.
Patients and methods
Between June 1992 and July 1997, 56 patients with IBC were enrolled in studies to evaluate outcomes following HDC with PBSC support. Patients were eligible if they had stage IIIB, T4d, IBC, were 65 years of age or less, had an ECOG performance of 0-1 and evidence of adequate hepatic, renal and cardiac function. All patients signed a protocol-specific informed consent approved by the institutional review board of the hospital where the therapy was administered.
Pre-treatment staging and disease classification
Staging procedures included computed tomography (CT) scans of head, chest and abdomen; contralateral mammography and radionuclide bone scan. Bone marrow biopsy was not required. Original source pathology documents were reviewed by two of the authors (LSS and RB) for confirmation and assignment of TNM staging system. 32 Inflammatory breast cancer was defined as histologically proven invasive adenocarcinoma of one breast with clinical inflammatory signs including rapid onset of painful ery-thema and brawny induration of the skin with an erysipeloid edge with or without an underlying mass. Histologic confirmation of dermal lymphatic involvement by tumor cells was not required for diagnosis. Hormone status was classified as ER/PRϩ if the tumor expressed receptors for estrogen and/or progesterone.
Treatment centers
Patients were treated in one of 25 participating medical centers in the United States under the care of 45 community oncologists affiliated with Response Oncology Inc. (ROI), Memphis, TN, USA, listed at the end of this manuscript. Chemotherapy for all phases of treatment was administered and PBSC harvested and infused in an outpatient facility. 33 Patients were admitted to hospitals meeting the criteria of the American Society of Clinical Oncology/the American Society of Hematology guidelines for stem cell transplantation. 34 
Sequence of treatment
The sequence of chemotherapy delivered depended on when patients were referred after diagnosis of IBC. Patients in the adjuvant group (n = 15) were referred after modified radical mastectomy and axillary lymph node dissection and received four to six courses of standard-dose doxorubicinbased chemotherapy prior to mobilization of PBSC. 24, 35 After clinicopathologic determination of IBC by core biopsy and physical examination, 24 patients in the neoadjuvant group received four courses of doxorubicin-based chemotherapy prior to definitive surgery and received mobilization chemotherapy after surgery. Seventeen patients in the neoadjuvant group were treated with doxorubicin-based induction and chemotherapy mobilization prior to mastectomy. 24, 35 All patients received high-dose chemotherapy with PBSC support after modified radical mastectomy and axillary lymph node dissection. 38 Granulocyte colony-stimulating factor (G-CSF, filgrastim; Amgen, Thousand Oaks, CA, USA), 6 g/kg/day, was administered after chemotherapy and continued until PBSC harvests by apheresis were complete. 36 Supportive care and details of PBSC harvesting, cryopreservation, thawing and infusion have been previously described. 35, 39 High-dose chemotherapy (CTCb) /day were administered in 1 h infusions on 3 consecutive days. 33 All patients received G-CSF 6 g/kg/s.c./day from the day of PBSC infusion until the ANC was Ͼ0.5 ϫ 10 9 /l for 3 consecutive days. Supportive care following the administration of HDC has been previously described. 40 
Mobilization, harvesting, cryopreservation and infusion of PBSC

Treatment after high-dose chemotherapy
Radiation therapy: Fifty patients (89%) received radiation therapy beginning a median of 50 days (range, 29-345) after infusion of PBSC and one patient received radiation therapy prior to HDC. External beam radiation therapy consisted of a total dose of 50 Gy to the chest wall, supraclavicular and internal mammary lymph nodes. Four patients did not receive radiation due to early death (n = 1), early relapse (n = 1) or patient refusal (n = 2) and one received only a single dose of radiation, had E. coli septicemia and died of respiratory failure 12 days later.
Hormonal therapy: Twenty-five of 26 patients who were ER/PRϩ and four who were ER/PRϪ received tamoxifen 20 mg/day after HDC until relapse.
Evaluation of response
Clinical responses were defined as complete remission (CR) if there was disappearance of all evidence of tumor and return of the breast to normal appearance. A partial remission (PR) was defined as at least 50% reduction in the sum of the products of the largest perpendicular diameters of measurable lesions or area of skin abnormalities without development of new lesions. Non-response was defined as ϽPR.
Follow-up
Patients were evaluated at 3 month intervals for the first 2 years following PBSC infusion and at 6 month intervals thereafter. Follow-up evaluations included physical examination and tests for tumor markers (CEA and CA 15.3) at each visit. Bone scan and chest radiograph were undertaken at yearly intervals. CT scans of chest, abdomen, brain and BM examinations were performed only when clinically indicated.
Statistics
Data were collected using a custom-designed distributed data system, reviewed at a central clinical trials center (ROI) and analyzed using the SAS system (SAS Institute, Cary, NC, USA). Proportions were compared using chisquare or Fisher's exact method, as appropriate. Probabilities of overall survival (OS), EFS and relapse were estimated using the product-limit method according to Kaplan and Meier and compared using the log-rank test. 41, 42 Time in survival analysis was calculated from the date of diagnosis to the endpoint censored for the date of last contact if the endpoint was not available. The endpoint for OS was the date of death; for EFS the date of relapse or death without relapse and for relapse the date of relapse. The date of latest follow-up was 1 December 1998. 
Results
Patient characteristics
Patient characteristics are shown in Table 2 summarizes the clinical and pathological responses observed in the 41 patients in the neoadjuvant group. Clinical CR or PR was observed in 27 of 33 evaluated patients (82%). Ten of 17 (59%) patients receiving induction and mobilization chemotherapy achieved a clinical CR compared to six of 24 (25%) receiving only induction therapy before surgery (P = 0.03). Pathologic CR of the primary tumor was observed in seven patients (17%), without significant differences by schedule of chemotherapy. The median number of positive axillary nodes in the neoadjuvant group was five (range 0-21), with nine patients having no positive lymph nodes. Patients in the adjuvant group had a median of 14 involved axillary lymph nodes (range 0-21) with only one patient having no positive nodes.
Clinical and surgical results following neoadjuvant chemotherapy
Outcomes following HDC
Hematopoietic recovery following PBSC infusion: A median of 12.5 ϫ 10 6 CD34 ϩ cells/kg (range 3.8-62.3) was infused. The median days to recovery of ANC Ͼ0.5 ϫ 10 9 /l Diffuse residual = lymph vascular involvement in all four quadrants of the breast; NED = no pathologic evidence of disease in breast, skin or lymph nodes.
and platelets Ͼ20 ϫ 10 9 /l were 9 (range 7-14) and 9 (range 0-17), respectively. A median of one packed red blood cell (range 0-4) and two (range 0-11) platelet transfusions were administered. Fifty-one patients (91%) were admitted to the hospital for a median of 11 days (range 5-25) and five patients were managed entirely in an outpatient setting.
Treatment-related mortality:
There were two treatmentrelated deaths (4%). One patient, age 60, in the adjuvant group died of acute respiratory failure following clinical sepsis syndrome 13 days after PBSC infusion. One patient, age 59, in the neoadjuvant group died of acute respiratory failure following E. coli septicemia 70 days after PBSC infusion. Both patients had sustained recovery of neutrophils Ͼ0.5 ϫ 10 9 /l. Relapses: Details of relapses are shown in Table 3 . Twenty-four patients (43%) have relapsed; four with localregional disease and 20 with metastatic disease. Sites of distant relapse included bone only (n = 5), brain only (n = 2), lung and/or pleura (n = 5), visceral (n = 3), liver only (n = 2), brain and liver (n = 1), and distant lymph node (n = 2). The probability of relapse at 3 years for all 56 patients was 0.44 with no difference observed between adjuvant and neoadjuvant groups.
Overall survival: Details of survival are shown in Table 3 . The probability of OS at 3 years for all 56 patients was 0.72 ( Figure 1 ). The probability of OS at 3 years for the 15 patients in the adjuvant group was 0.65 compared to 0.74 for the 41 in the Neoadjuvant Group (P = 0.88). The probability of OS at 3 years for 24 patients receiving mobilization chemotherapy after surgery was 0.74 compared to 0.76 for 17 patients receiving mobilization chemotherapy before surgery (P = 0.41). Event-free survival: Details of EFS are shown in Table 3 . The probability of EFS at 3 years for all 56 patients was 0.53 ( Figure 1 ). The probability of EFS at 3 years for the 15 patients in the adjuvant group was 0.52 compared to 0.55 for the 41 in the neoadjuvant group (P = 0.75). The probability of EFS at 3 years for 24 patients receiving mobilization chemotherapy after surgery was 0.56 compared to 0.53 for 17 patients receiving mobilization chemotherapy before surgery (P = 0.72). Event-free survival in the neoadjuvant group was analyzed based on response to induction chemotherapy. The following subgroups were included in a univariate analysis: achievement of clinical complete remission, clinical CR or PR, pathologic CR in the breast, pathologic CR in breast and lymph nodes and number of involved lymph nodes. No factors could be identified that were statistically associated with a better or worse outcome.
Discussion
Although there is large variability between studies, approximately 30% of patients with stage IIIB IBC have prolonged EFS following conventional neoadjuvant chemotherapy. 1, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Increased dose intensity without stem cell support has been associated with improved outcomes in some 9 but not other studies.
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There is limited information concerning the effects of HDC with stem cell support in patients with IBC. The International Bone Marrow Transplant Registry has reported a 42% EFS at 3 years for 224 patients with IBC receiving HDC with hematopoietic stem cell support. 23 However, there were no details concerning the sequence of therapy or surgical results in these patients. 23 Ayash et al 30 treated 42 patients with stage IIIB inflammatory disease with single agent doxorubicin induction and high-dose CTCb with BM support followed by surgery. They observed a 3 year EFS of 64% with a median follow-up of 27 months (range 4-53) from the time of HDC. Somlo et al 43 reported OS and EFS of 72% and 54%, respectively, for 22 patients with IBC receiving HDC with a median follow-up of 3.5 years.
Cagnoni et al
31 treated 30 patients with high-dose cyclophosphamide, cisplatin and carmustine with stem cell support after surgery. With a median follow-up of 23.5 months from diagnosis, the probability of EFS was approximately 60% at 30 months. Adkins et al 44 reported an EFS of 57% with a median follow-up of 26.5 months for 21 patients with IBC receiving HDC with stem cell support.
The current study represents the largest group of patients with the longest follow-up with IBC treated with HDC and PBSC support. Our results show an EFS of 53% and an OS of 72% at 3 years with a median follow-up of 44 months. In the current study, HDC with PBSC support was delivered in an outpatient setting after mastectomy and lymph node dissection with 51 of 56 patients requiring admission to the hospital for a median of 11 days (5-25) with five patients receiving all treatment as outpatients.
All patients in the current study received standard-dose induction chemotherapy, chemotherapy mobilization of PBSC and high-dose CTCb with the only difference between groups being the sequence of therapy. Treatment sequencing was dictated by referral patterns with most patients being entered on study after surgery or after induction chemotherapy and surgery. Seventeen patients enrolled at diagnosis were treated on a protocol evaluating chemotherapy induction, chemotherapy mobilization of PBSC, surgery and HDC. The currently favored approach to the treatment of locally advanced breast cancer is to administer neoadjuvant chemotherapy before surgery in order to optimize surgical resection and local control. 8 The exact contribution of neoadjuvant, compared to adjuvant chemotherapy, to local control or the prevention of distant relapses is not clear. 45 In the current study there were four local-regional relapses, 1/15 (7%) in the adjuvant group and 3/41 (7%) in the neoadjuvant group. Thus, there was no apparent detrimental effect from surgery as the first therapeutic intervention, in patients receiving aggressive chemotherapy and radiotherapy postoperatively. However, given the small numbers and heterogeneity of patients evaluated differences could have been missed.
Clinical disappearance of macroscopic disease has been associated with improved survivals. 46 However, Chevallier et al, 12 in sequential trials of progressively more intensive induction therapy in 178 patients, observed an increase in clinical response rates but no impact on the approximate 25% EFS at 5 years. In the current study there were no significant differences in EFS between patients achieving or not achieving a clinical CR before HDC. There was no significant correlation between extent of residual disease at surgery following neoadjuvant chemotherapy and EFS following HDC. Five of 41 patients (12%) receiving neoadjuvant therapy in this study achieved a pathologic CR in both breast and axilla before HDC, which was similar to the 14% achieved following HDC in the study by Ayash et al 30 where a superior EFS for patients was observed in patients without residual gross disease. Four of the five patients who achieved a pathologic CR remain disease free at 16, 43, 53 and 64 months from diagnosis. More patients with a pathologic CR will have to be evaluated before relationships between residual disease and EFS can be accurately evaluated especially in patients who receive HDC after surgery.
Whether or not HDC is superior to intensive chemotherapy without stem cell support in patients with IBC is impossible to determine by comparing published reports. The 3 year EFS of 42% to 64% for patients with IBC receiving HDC are generally higher than most reported studies of conventional neoadjuvant therapy. 23, 30, 31, 43, 44 However, there have been reports of EFS of 40-56% at 4-5 years following neoadjuvant chemotherapy delivered without stem cell support. [8] [9] [10] An obvious approach would be to perform a randomized trial comparing HDC with stem cell support to intensive neoadjuvant chemotherapy without stem cell support. Since IBC comprises only 1-4% of all breast cancer patients, randomized trials comparing conventional to HDC would be difficult to perform even by large cooperative groups. Given that at least 40% of patients in the current and other studies have relapsed it may be more important to improve therapy than to compare different sub-optimal therapies. New approaches incorporating taxanes into induction or HDC regimens, alternative HDC regimens or post-transplant chemotherapy or immunotherapy may further improve results in this disease.
